top of page

ANAVEX New Website - Untitled Page.png

Search

A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in AD

Mar 25, 2014

International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (2014), Geneva, Switzerland

A. Fisher, R. Medeiros, N. Bar-Ner, N. Natan, R. Brandeis, H. Elkon, V. Nahum, G. Grigoryan, M. Segal and F. Laferla

View Poster

Recent Posts

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

bottom of page